DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T?cell responses that potentiate cell therapy for fibrolamellar carcinoma.

DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T?cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep Med. 2024 Mar 19; 5(3):101469.

View in: PubMed

subject areas

Carcinoma, Hepatocellular
Cell- and Tissue-Based Therapy
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
HSP40 Heat-Shock Proteins
Humans
Receptors, Antigen, T-Cell
T-Lymphocytes